Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07146022 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
A Phase 3 study of Androgenetic Alopecia and Hair Loss, sponsored by Veradermics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 552
- Enrollment target
- 20
- Study locations
NCT07146022: Recruiting Phase 3 study of Androgenetic Alopecia and Hair Loss, sponsored by Veradermics.
NCT07146022 is a Phase 3 study of Androgenetic Alopecia and Hair Loss that is actively recruiting participants, run by Veradermics. The registered enrollment target is 552 participants, above the 130-participant average among 16 other Androgenetic Alopecia trials with a reported enrollment target (325% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07146022, a Phase 3 study of Androgenetic Alopecia and Hair Loss, is actively recruiting participants, sponsored by Veradermics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 552 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety and efficacy of VDPHL01 in female subjects with Androgenetic Alopecia (AGA). AGA is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormones) that causes hair loss. VDPHL01 is an investigational oral drug to treat AGA. This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13).
Primary Outcome
Changes from baseline in non-vellus TAHC using digital image analysis at Month 6.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VDPHL01 QD
- DRUG VDPHL01 BID
Study Locations (20)
California
- Site 69 - Encino
- Site 2 - Fremont
- Site 64 - Manhattan Beach
- Site 93 - Northridge
- Site 66 - Santa Monica
- Site 34 - Sherman Oaks
- Site 94 - Thousand Oaks
- Site 21 - Vista
Florida
- Site 17 - Aventura
- Site 71 - Boca Raton
- Site 86 - Coral Gables
- Site 62 - Coral Gables
- Site 99 - Miami
- Site 54 - Ocala
Alabama
- Site 73 - Birmingham
- Site 89 - Birmingham
Colorado
- Site 5 - Castle Rock
- Site 24 - Greenwood Village
Arizona
- Site 77 - Phoenix
Arkansas
- Site 30 - Fort Smith
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 552 participants |
| Start Date | 2025-07-25 |
| Est. Completion | 2028-01 |
| Phase | Phase 3 |
What NCT07146022 shows while recruiting
NCT07146022 is an interventional study that assigns participants to a tested intervention. The registered 552 participants enrollment target is mid-sized for trials with a published cap, above the 130-participant average among 16 other Androgenetic Alopecia trials with a reported enrollment target (325% higher).
The record links to 5 conditions, with Androgenetic Alopecia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07146022 names 20 study sites across 6 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT07146022 about?
NCT07146022 is a clinical study titled "Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)". This study will evaluate the safety and efficacy of VDPHL01 in female subjects with Androgenetic Alopecia (AGA). AGA is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormones) that causes hair loss. VDPHL01 is an investigational oral drug to treat AGA. T...
What is the current status of trial NCT07146022?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 552 participants. The study started on 2025-07-25. Estimated completion is 2028-01.
What conditions does trial NCT07146022 study?
This clinical trial studies the following conditions: Androgenetic Alopecia, Hair Loss, AGA, Androgenetic Alopecia (AGA), Female Androgenetic Alopecia.
What interventions are being tested in trial NCT07146022?
The interventions under investigation include: Placebo (DRUG), VDPHL01 QD (DRUG), VDPHL01 BID (DRUG).
Who is sponsoring clinical trial NCT07146022?
This trial is sponsored by Veradermics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07146022 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Androgenetic Alopecia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07146022's enrollment target sits among peer trials
552 1st of 16 higher than 16 of 16 other Androgenetic Alopecia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Androgenetic Alopecia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Efficacy of VDPHL01 in Males With AGA
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss
COMPLETED · Phase 3
-
Sham LaserCap vs. LaserCap SD vs. LaserCap HD+
RECRUITING · NA
-
1470nm Laser for the Treatment of Androgenetic Alopecia and Scarring Alopecia
RECRUITING · NA
-
Safety and Efficacy of VDPHL01 in Males and Females With AGA
ACTIVE NOT RECRUITING · Phase 2
-
Use of Botulinum Toxin in the Treatment of Androgenic Alopecia
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06217809 · 552 participants · NA
EmpowHer is Prevention Curriculum for Youth Ages 10-15 Years.
- NCT05786924 · 554 participants · Phase 1
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- NCT01852448 · 550 participants
Genetics of Insulin and Incretins in Cystic Fibrosis
- NCT02995252 · 550 participants
The HOPE Study: Characterizing Patients With Hepatitis B and C
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI